ImmunoScape enables the characterization of a patient’s immune profile at unprecedented resolution. Our assays provide a view into the immune system in action, directly observing T cell phenotype & function with simultaneous tracking of TCR-antigen binding.
Our platform delivers key insights on antigen-specific T cells in studies of immune checkpoint blockade, therapeutic and prophylactic vaccines, and T cell therapy, empowering researchers and drug developers.
Discover novel vaccine, antibody, or cell therapy targets
Evaluate treatment outcomes through longitudinal studies
Design successful clinical trials through efficient patient enrollment
Uncover combinations of predictive biomarkers of disease or treatment efficacy
Demonstrate proof-of-mechanism in tissues of interest
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
Our platform delivers key insights on antigen-specific T cells in studies of immune checkpoint blockade, therapeutic and prophylactic vaccines, and T cell therapy, empowering researchers and drug developers.
Discover novel vaccine, antibody, or cell therapy targets
Evaluate treatment outcomes through longitudinal studies
Design successful clinical trials through efficient patient enrollment
Uncover combinations of predictive biomarkers of disease or treatment efficacy
Demonstrate proof-of-mechanism in tissues of interest
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
Location: Singapore
Employees: 11-50
Total raised: $49M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Anzu Partn... | anzupartne... |
| - | The Univer... | ut-ec.co.j... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 20.09.2022 | - | $24M | - |
| 06.05.2021 | - | $14M | - |
| 12.08.2020 | - | $11M | Anzu Partn... |
Mentions in press and media 14
| Date | Title | Description |
| 17.06.2025 | [Updated] EDBI emerges as SG biotech firm ImmunoScape's second-largest shareholder | Editor’s note: An earlier version of this story, published on June 13, stated that ImmunoScape has secured fresh funding from EDBI. The article has been updated to clarify that EDBI was issued preference shares as part of a conversion of a ... |
| 20.09.2022 | ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-Cell Receptors | We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Cookie settingsACCEPT |
| 20.09.2022 | ImmunoScape Finds $24M From Amgen, Others | San Diego-based ImmunoScape, a biotech company which says it is focused on discovery and development of next-generation TCR-T-cell therapeutics, has raised $14M in a funding round. The funding was led by Anzu Partners, and also included Amg... |
| 20.09.2022 | ImmunoScape Raises $14M in Funding | ImmunoScape, a San Diego, CA and Singapore-based pre-clinical biotechnology company, raised $14M in funding. The round was led by Anzu Partners, with participation from Amgen Ventures and EDBI. The company intends to use the funds to expedi... |
| 29.04.2021 | ImmunoScape Raises $14 Million | ImmunoScape, a biotech company which specializes in cancer treatment, has raised $14 million fundraising round. ... Take 1 minute to subscribe and you'll get this story immediately, plus: Already a subscriber? Sign in 52 weekly issues Subsc... |
| 14.04.2021 | ImmunoScape : Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery | ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round led by existing investors Anzu Partners,... |
| 14.04.2021 | ImmunoScape has raised a $14M funding round to further expand into the US and scale up its newly announced San Diego laboratory | - |
| 14.04.2021 | ImmunoScape Raises $14M in Funding | ImmunoScape, a Singapore and San Diego, CA-based biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, completed a $14m funding round. The round, which brought total funding ... |
| 14.04.2021 | ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery | We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Cookie settingsACCEPT |
| 12.08.2020 | ImmunoScape Raises $11M in Financing | ImmunoScape, a Singapore-based biotech firm enabling insights into the human immune system, raised USD $11m (SGD $14.8m) in equity financing. US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTE... |
Show more